Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific hails commercial launch of breakthrough cancer detection device

The official launch took place in San Francisco at the Molecular Medicine Tri Conference.
NetScientific hails commercial launch of breakthrough cancer detection device
The fully-automated technology is able to collect circulating tumour cells
NetScientific PLC (LON:NSCI) said its investee company Vortex Biosciences has begun the commercial launch of its VTX1 Liquid Biopsy System.
 
The fully-automated technology offers a breakthrough in early cancer detection in that it is able to collect circulating tumour cells (CTC) from the bloodstream that provide the tell-tale sign of the killer disease.
 
"We believe the technology has several key advantages over current approaches to CTC isolation and has the potential to make a meaningful impact on cancer research and assist the development of innovative diagnostics and therapeutics," said NetScientific chief executive François Martelet. 
 
"The commercial launch is a critical milestone for Vortex and brings our portfolio company closer to significant value creation."
 
The AIM-listed investment company owns 95% of Votex having invested just over £13mln in the business.
 
The official launch took place in San Francisco at the Molecular Medicine Tri Conference.
 
Ian_55ae0ddd437b7.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of blood phials
May 11 2017
“2017 is off to a strong start and …we look forward to achieving additional milestones in the second quarter."
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use